United States· US:0143-9144_4e2acb7a-d32d-49d3-b59b-39332b5809f3
Liraglutide
A liraglutide product containing liraglutide, registered in United States by Hikma Pharmaceuticals USA Inc.. The same ATC class is registered in 16 of our 19 countries.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
Where it is registered
Liraglutide is registered in 16 of 19 countries.
Countries holding a registration under ATC A10BJ02 (liraglutide), each read from that country’s own register.
- This record: United States, from FDA National Drug Code directory (United States)
- 10 of them publish a price we can compare per daily dose
Liraglutide · ATC A10BJ02
16 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- LIRAGLUTIDE
- Manufacturer
- Hikma Pharmaceuticals USA Inc.
- Country
- United States (US)
- ATC code
- A10BJ02
- ATC class
- Liraglutide
- Defined daily dose
- 1.5 mg, P
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- September 27, 2026
Packs & prices · 2
- ndc110143-9144-02
- ndc110143-9144-03
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
309 interactions on record for liraglutide.
Graded by severity as the source publishes them — 3 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Liraglutide · interactions on record
309 records
- 3 severe
- 260 moderate
- 46 minor
Most severe, free to view
- GatifloxacinJ01MA16severe
- SucralfateA02BX02moderate
- ThiethylperazinA04AB03moderate
- TriflupromazinA04AD06moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Liraglutide in 17 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaABLYMICOSTADA Arzneimittel AG, Bad Vilbel
- SpainBYESILOR 6 MG/ML SOLUCION INYECTABLE EN PLUMA PRECARGADA EFGSun Pharmaceutical Industries (Europe) B.V.
- SwedenAblymico 6 mg/ml Injektionsvätska, lösning i förfylld injektionspennaSTADA Arzneimittel AG
- United KingdomBiolide 6mg/ml solution for injection 3ml pre-filled pensBiocon Pharma UK Ltd
- NetherlandsAblymico 6 mg/ml oplossing voor injectie in een voorgevulde penStada Arzneimittel AG
- PolandAblymicoSTADA Arzneimittel AG
- GermanyByesilorBasics Gmbh
- FinlandAblymicoSTADA Arzneimittel AG
Authorised across Europe · EMA
The same active substance is authorised in 27 EEA countries. Names it is sold under:
- Austria · Ejulir, Lirabelin
- Belgium · Byesilor, Zinnentis
- Bulgaria · Зеглуксен
- Czechia · Ejulir, Plyzari
- Germany · Byesilor, Diavic
- Denmark · Ejulir, Liraglutid "biogaran"
- Estonia · Liraglutide Zentiva, Siluxir
- Spain · Byesilor, Diavic
- Finland · Diavic, Metlyra
- France · Liendax, Liraglutide Biogaran
- United Kingdom (Northern Ireland) · Diavic, Ligobesy
- Croatia · Zegluxen
- Hungary · Liendax
- Ireland · Ejulir
- Iceland · Ablymico, Liraglutide Stada
- Italy · Byesilor, Diavic
- Liechtenstein · Ablymico, Liraglutide Stada
- Lithuania · Liraglutide Zentiva
- Luxembourg · Zinnentis
- Latvia · Liraglutide Zentiva, Siluxir
- Netherlands · Byesilor, Diavic
- Norway · Ablymico, Liraglutid Zentiva
- Poland · Byesilor, Diavic
- Portugal · Liraglutido Farmoz, Liraglutido Pentafarma
- Romania · Byesilor, Diavic
- Sweden · Diavic, Ejulir
- Slovakia · Sudaclin
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/f85192cd-59ab-49ce-878c-4bbe4ca51d61 GET /v1/drugs/f85192cd-59ab-49ce-878c-4bbe4ca51d61?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "SUBCUTANEOUS",
"source": "ndc",
"strength": "6",
"substance": "LIRAGLUTIDE",
"productndc": "0143-9144",
"dosage_form": "INJECTION",
"dea_schedule": null,
"strength_unit": "mg/mL",
"application_number": "ANDA215503",
"marketing_category": "ANDA"
}See everything about liraglutide.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.